NewSquare Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

NewSquare Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-53	Closed	-$27.8K	–	985
2025 Q2	$27.8K	Buy	53 +7	+15%	+$3.91K	﹤0.01%	412
2025 Q1	$29.2K	Buy	46 +42	+1,050%	+$28.9K	﹤0.01%	299
2024 Q4	$2.85K	Buy	+4	New	+$3.36K	﹤0.01%	459
2023 Q4	–	Sell	-26	Closed	-$21.4K	–	604
2023 Q3	$21.4K	Buy	26 +24	+1,200%	+$18.9K	﹤0.01%	238
2023 Q2	$1.44K	Sell	2 -29	-94%	-$22.4K	﹤0.01%	564
2023 Q1	$25.5K	Buy	31 +29	+1,450%	+$21.9K	﹤0.01%	247
2022 Q4	$1.44K	Buy	+2	New	+$1.48K	﹤0.01%	531
2022 Q1	–	Sell	-9	Closed	-$6K	–	447
2021 Q4	$6K	Hold	9	–	–	﹤0.01%	317
2021 Q3	$5K	Hold	9	–	–	﹤0.01%	319
2021 Q2	$5K	Hold	9	–	–	﹤0.01%	306
2021 Q1	$4K	Hold	9	–	–	﹤0.01%	298
2020 Q4	$4K	Buy	+9	New	+$4.86K	﹤0.01%	302
2016 Q4	–	Sell	-14	Closed	-$6K	–	419
2016 Q3	$6K	Hold	14	–	–	﹤0.01%	293
2016 Q2	$5K	Sell	14 -2	-13%	-$770	﹤0.01%	289
2016 Q1	$6K	Buy	+16	New	+$6.59K	﹤0.01%	341

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NewSquare Capital's REGN Position: Q3 2025 in Review

NewSquare Capital sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 53 shares — an estimated $27.8K sold.

NewSquare Capital first reported a position in REGN in Q1 2016 and held it in 15 quarters. The position peaked at $29.2K in Q1 2025. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

NewSquare Capital reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
NewSquare Capital sold 53 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $27.8K.
NewSquare Capital first reported a position in Regeneron Pharmaceuticals in Q1 2016 and held it in 15 quarters.
NewSquare Capital's Regeneron Pharmaceuticals position peaked at $29.2K in Q1 2025.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on NewSquare Capital's 13F filing for Q3 2025, filed 12 Nov 2025.